Search review questions

Participants discharged alive. Participants should be discharged without clinical deterioration or death · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Quality of life up to 28 days and longest · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

SAEs during the study period · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Any grade TEAE · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Any grade TRAE · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Admission to hospital or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Viral clearance · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Viral clearance at 7 days · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Viral clearance at 14 days · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Admission to ICU or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Time to symptom resolution · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Quality of life up to 28 days and longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

SAEs during the study period · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Any grade TEAE · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Any grade TRAE · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Malaria infection incidence alone( · adults and children in malaria‐endemic areas

Malaria case incidence alone( · adults and children in malaria‐endemic areas

Malaria case and infection incidence together ( · adults and children in malaria‐endemic areas

Adverse events · adults and children in malaria‐endemic areas

Malaria prevalence ( · adults and children in malaria‐endemic areas

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 42 (unadjusted) · adults and children with uncomplicated P falciparum malaria

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

Total failure: day 28 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 42 (PCR‐adjusted) · adults and children with uncomplicated P falciparum malaria

Total failure: day 42 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria

First treatment, abnormal ALT increase (42 days) · adults and children with uncomplicated P falciparum malaria

First treatment, abnormal AST increase (42 days) · adults and children with uncomplicated P falciparum malaria

First treatment, abnormal bilirubin increase (42 days) · adults and children with uncomplicated P falciparum malaria

Outcomesa,b,c · adults and children with uncomplicated malaria

Serious adverse events · adults and children with uncomplicated malaria

First treatment, abnormal ALT increase · adults and children with uncomplicated malaria

First treatment, abnormal AST increase · adults and children with uncomplicated malaria

First treatment, abnormal bilirubin increase · adults and children with uncomplicated malaria

Total failure: day 28 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Subsequent treatment(s), abnormal ALT increase · adults and children with uncomplicated malaria

Subsequent treatment(s), abnormal AST increase · adults and children with uncomplicated malaria

Subsequent treatment(s), abnormal bilirubin increase · adults and children with uncomplicated malaria

Total failure: day 42 (unadjusted) · adults and children with uncomplicated P falciparum malaria

Serious adverse events (42 days) · adults and children with uncomplicated P falciparum malaria